Comparing the current results to its competitors, Argenx Se reported Revenue increase in the 4 quarter 2025 by 89.08 % year on year. The sales growth was above Argenx Se's competitors' average revenue growth of 34.89 %, achieved in the same quarter.
Argenx Se's Comment on Competition and Industry Peers
The company operates in a competitive environment with other biopharmaceutical firms developing or marketing treatments for generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), and various autoimmune diseases. Competitors offer products within the same class as VYVGART and similar product candidates. Competition extends to potential future indications, with significant development activity by competitors across nearly all areas the company is pursuing. New product launches by competitors may affect the company's future sales or lead to product obsolescence. Additionally, the company may encounter competition for limited international infusion sites as new products are introduced. The timing and effects of competitive product launches are uncertain. Competitors also vie for qualified personnel across all operational areas of the company.
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
Intensity Therapeutics Inc's business model involves developing and commercializing novel intratumoral cancer immunotherapy products. They aim to target and destroy tumors within the body through the direct application of their proprietary drug, leading to an enhanced immune response and potential treatment for various cancers.
Mink Therapeutics Inc is a biotechnology company that focuses on developing mRNA therapeutics for treating genetic diseases. Their business model primarily revolves around utilizing messenger RNA (mRNA) to develop and deliver novel therapies that can address genetic disorders. By leveraging the potential of mRNA technology, Mink Therapeutics aims to offer innovative treatments that have the ability to fundamentally transform the field of genetic medicine.
Inhibrx Inc operates using a business model that focuses on the development and commercialization of therapeutics. The company leverages its innovative technology platform to create a diverse pipeline of biologics for the treatment of various diseases. Inhibrx Inc aims to collaborate with strategic partners to advance the development of its pipeline and expand its reach in the healthcare market.
Immunovant Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases by leveraging their expertise in research and development, clinical trials, and regulatory approvals. Their business model revolves around discovering innovative treatments, conducting rigorous testing, and seeking regulatory clearance to bring their products to market and improve patient outcomes.
Sources:
Argenx Se’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Argenx Se versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
